Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from High Tide ( (TSE:HITI) ) is now available.
On September 1, 2025, High Tide Inc. completed the acquisition of 51% of Remexian Pharma GmbH for approximately €26.4 million. This strategic acquisition, which includes an option to acquire the remaining interest in Remexian, is expected to enhance High Tide’s market position and operational capabilities in the pharmaceutical sector. The transaction was structured with a combination of cash, common shares, and loans, and reflects High Tide’s growth strategy to expand its footprint in the cannabis and pharmaceutical markets.
The most recent analyst rating on (TSE:HITI) stock is a Buy with a C$5.00 price target. To see the full list of analyst forecasts on High Tide stock, see the TSE:HITI Stock Forecast page.
Spark’s Take on TSE:HITI Stock
According to Spark, TipRanks’ AI Analyst, TSE:HITI is a Neutral.
High Tide’s overall stock score is driven by strong financial performance and positive earnings call sentiment, highlighting growth in retail expansion and market share. However, the technical indicators suggest the stock may be overbought, and the negative P/E ratio reflects ongoing profitability challenges.
To see Spark’s full report on TSE:HITI stock, click here.
More about High Tide
High Tide Inc. operates in the cannabis industry, focusing on the acquisition and management of cannabis-related businesses. The company is based in Calgary, Alberta, Canada.
Average Trading Volume: 93,330
Technical Sentiment Signal: Strong Buy
Current Market Cap: C$427.5M
See more data about HITI stock on TipRanks’ Stock Analysis page.